Neuberger Quoted in BNA Labor and Employment Blog on the Impact of Right-to-Work Laws
21 August 2017
Of Counsel Mark Neuberger was quoted in the Bloomberg BNA Labor and Employment Law blog, “Punching In: Labor Department Personnel Moves and More,” discussing why unions are less likely to file election petitions in states that ban labor organizations from requiring workers to pay representation and administrative fees.
Unions may be filing fewer petitions in those states because there are fewer groups of workers they can convince to back them. “The conventional wisdom is that they don’t file any petitions unless they have close to 50 percent support,” Neuberger said.
Read more on Bloomberg BNA’s website here.
Unions may be filing fewer petitions in those states because there are fewer groups of workers they can convince to back them. “The conventional wisdom is that they don’t file any petitions unless they have close to 50 percent support,” Neuberger said.
Read more on Bloomberg BNA’s website here.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”